Skip to main content

Table 3 Drug treatment and vaccinations of the studied COPD patients, according to gender and smoking habit.

From: Characteristics of chronic obstructive pulmonary disease in Spain from a gender perspective

Treatment

Male non-smokers

Male smokers

Female non-smokers

Female smokers

Short-acting β2-adrenergic agonists (%)*

(216) 33.4

(2927) 39.8

(685) 38.0

(289) 37.4

Long-acting β2-adrenergic agonists (%)

(53) 8.2

(735) 10.0

(149) 8.3

(55) 7.1

Anticholinergic agents (%)†

(549) 84.8

(6304) 85.7

(1489) 82.6

(635) 82.1

Theophyllines (%)†

(64) 9.9

(986) 13.4

(155) 8.6

(42) 5.4

Inhalatory corticoids (%)+†Ŧ

(123) 19.0

(1648) 22.4

(441) 24.4

(130) 16.8

Oral corticoids (%)

(27) 4.2

(331) 4.5

(105) 5.8

(31) 4.0

Mucolytic agents (%)†

(50) 7.7

(692) 9.4

(151) 8.4

(48) 6.2

Antiinfluenza vaccine in last campaign (%)+†

(547) 85.3

(6409) 88.3

(1585) 88.9

(568) 74.8

Antipneumococcal vaccination at some time in past (%)+†

(210) 33.5

(2332) 32.8

(618) 35.5

(150) 20.2

  1. * Significant difference in the comparison of male smokers versus male non-smokers.
  2. + Significant difference in the comparison of female smokers versus female non-smokers.
  3. † Significant difference in the comparison of male smokers versus female smokers, after adjusting by age and severity
  4. Ŧ Significant difference in the comparison of male non-smokers versus female non-smokers, after adjusting by age and severity.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us